NeuroOne Medical Technologies
NMTC
26 hedge funds and large institutions have $6.21M invested in NeuroOne Medical Technologies in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 12 closing their positions.
19.6% more ownership
Funds ownership: 3.88% → 23.49% (+20%)
19% less funds holding
Funds holding: 32 → 26 (-6)
32% less capital invested
Capital invested by funds: $9.14M → $6.21M (-$2.93M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$490K |
| 2 |
BlackRock
New York
|
+$103K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$61.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$157K |
| 2 |
State Street
Boston,
Massachusetts
|
-$46.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$36.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$33.6K |
| 5 |
JWCA
J.W. Cole Advisors
Tampa,
Florida
|
-$28K |
NMTC Hedge Fund Activity: Q2 2026 in Review
26 of the 8,323 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q2 2026, worth a combined $6.21M — down 32% from $9.14M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NMTC and 6 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Capital Management, adding an estimated $490K. The largest seller was Renaissance Technologies, cutting an estimated $157K.
- 26 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q2 2026, down from 32 in Q1 2026.
- Funds reported $6.21M of NeuroOne Medical Technologies stock for Q2 2026, down 32% quarter-over-quarter.
- 6 funds opened new NeuroOne Medical Technologies positions in Q2 2026 and 12 closed out, a net change of -6 holders.
- The largest NeuroOne Medical Technologies buyer in Q2 2026 was Vanguard Capital Management, an estimated $490K added.
- The largest NeuroOne Medical Technologies seller in Q2 2026 was Renaissance Technologies, an estimated $157K sold.
Based on aggregated 13F filings for Q2 2026.